Shineco, Inc. (SISI)
USD 0.87
(-3.32%)
USD 0.87
(-3.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 47.6 Million USD | 78.85% |
| 2023 | 26.61 Million USD | -12.77% |
| 2022 | 30.51 Million USD | 91.42% |
| 2021 | 15.94 Million USD | 26.75% |
| 2020 | 12.57 Million USD | 13.22% |
| 2019 | 11.1 Million USD | 8.61% |
| 2018 | 10.22 Million USD | 103.27% |
| 2017 | 5.03 Million USD | -23.05% |
| 2016 | 6.53 Million USD | 10.39% |
| 2015 | 5.92 Million USD | 57.56% |
| 2014 | 3.75 Million USD | -52.38% |
| 2013 | 7.89 Million USD | 0.0% |
| 2006 | 2.75 Million USD | 0.0% |
| 2005 | 2.75 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 47.6 Million USD | -13.43% |
| 2024 Q3 | 54.98 Million USD | 6.49% |
| 2024 Q2 | 51.63 Million USD | 9.9% |
| 2024 Q1 | 46.98 Million USD | 76.51% |
| 2023 Q2 | 21.63 Million USD | -0.28% |
| 2023 Q4 | 26.61 Million USD | 5.78% |
| 2023 Q3 | 25.16 Million USD | 16.32% |
| 2023 FY | 26.61 Million USD | -12.77% |
| 2023 Q1 | 21.69 Million USD | -28.91% |
| 2022 Q3 | 31.54 Million USD | -4.16% |
| 2022 Q1 | 31.61 Million USD | 98.32% |
| 2022 FY | 30.51 Million USD | 91.42% |
| 2022 Q2 | 32.91 Million USD | 4.13% |
| 2022 Q4 | 30.51 Million USD | -3.28% |
| 2021 Q2 | 15.04 Million USD | -0.21% |
| 2021 Q3 | 15.74 Million USD | 4.65% |
| 2021 FY | 15.94 Million USD | 26.75% |
| 2021 Q4 | 15.94 Million USD | 1.23% |
| 2021 Q1 | 15.07 Million USD | 19.9% |
| 2020 FY | 12.57 Million USD | 13.22% |
| 2020 Q3 | 11.47 Million USD | 7.75% |
| 2020 Q4 | 12.57 Million USD | 9.58% |
| 2020 Q1 | 10.62 Million USD | -4.33% |
| 2020 Q2 | 10.65 Million USD | 0.24% |
| 2019 Q1 | 8.66 Million USD | -15.25% |
| 2019 Q2 | 9.29 Million USD | 7.27% |
| 2019 Q3 | 11.57 Million USD | 24.46% |
| 2019 Q4 | 11.1 Million USD | -4.02% |
| 2019 FY | 11.1 Million USD | 8.61% |
| 2018 Q2 | 7.75 Million USD | 46.57% |
| 2018 Q3 | 10.5 Million USD | 35.43% |
| 2018 Q4 | 10.22 Million USD | -2.68% |
| 2018 FY | 10.22 Million USD | 103.27% |
| 2018 Q1 | 5.29 Million USD | 5.23% |
| 2017 FY | 5.03 Million USD | -23.05% |
| 2017 Q4 | 5.03 Million USD | -7.63% |
| 2017 Q3 | 5.44 Million USD | -10.77% |
| 2017 Q2 | 6.1 Million USD | -10.07% |
| 2017 Q1 | 6.78 Million USD | 3.82% |
| 2016 Q4 | 6.53 Million USD | 8.44% |
| 2016 Q3 | 6.02 Million USD | -10.55% |
| 2016 Q2 | 6.74 Million USD | 13.39% |
| 2016 Q1 | 5.94 Million USD | 0.36% |
| 2016 FY | 6.53 Million USD | 10.39% |
| 2015 Q2 | 5.11 Million USD | 0.0% |
| 2015 Q4 | 5.92 Million USD | 6.4% |
| 2015 Q3 | 5.56 Million USD | 8.83% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 5.92 Million USD | 57.56% |
| 2014 Q3 | 11.02 Million USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2014 FY | 3.75 Million USD | -52.38% |
| 2014 Q4 | 3.75 Million USD | -65.91% |
| 2013 FY | 7.89 Million USD | 0.0% |
| 2013 Q4 | 5.79 Million USD | 0.0% |
| 2007 Q2 | 3.52 Million USD | 27.72% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q1 | 2.75 Million USD | 0.0% |
| 2006 FY | 2.75 Million USD | 0.0% |
| 2006 Q3 | 3.27 Million USD | 0.0% |
| 2006 Q1 | 3.03 Million USD | 0.0% |
| 2005 FY | 2.75 Million USD | 0.0% |
| 2005 Q3 | 2.82 Million USD | 2.42% |
| 2005 Q2 | 2.75 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 660.79 Million USD | 92.796% |
| Theratechnologies Inc. | 98.63 Million USD | 51.742% |
| Safety Shot Inc | 3.89 Million USD | -1123.051% |
| Cosmos Health Inc. | 30.25 Million USD | -57.348% |
| Cronos Group Inc. | 43.73 Million USD | -8.838% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 94.176% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 1.741% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 73.753% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -246.085% |
| ProPhase Labs, Inc. | 42.54 Million USD | -11.888% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -443.646% |
| Dynavax Technologies Corporation | 375.02 Million USD | 87.307% |
| Radius Health, Inc. | 804.29 Million USD | 94.082% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -417.6% |
| Alvotech | 1.88 Billion USD | 97.471% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -675.322% |
| Alpha Teknova, Inc. | 38.55 Million USD | -23.477% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 65.221% |
| SCYNEXIS, Inc. | 55.45 Million USD | 14.154% |
| Harrow Health, Inc. | 241.75 Million USD | 80.31% |
| Biofrontera Inc. | 23.13 Million USD | -105.721% |
| DURECT Corporation | 30.4 Million USD | -56.554% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 90.235% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 89.908% |
| OptiNose, Inc. | 194.33 Million USD | 75.505% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -126.911% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 70.958% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 9.358% |
| SIGA Technologies, Inc. | 57.97 Million USD | 17.896% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 78.343% |
| Phibro Animal Health Corporation | 725.54 Million USD | 93.439% |
| Procaps Group S.A. | 462.06 Million USD | 89.698% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -239.479% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -21585.231% |
| Viatris Inc. | 27.21 Billion USD | 99.825% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -675.322% |
| Rockwell Medical, Inc. | 30.88 Million USD | -54.141% |
| Incannex Healthcare Limited | 5.83 Million USD | -716.495% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 47.331% |
| Tilray Brands, Inc. | 892.11 Million USD | 94.664% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 94.978% |
| PetIQ, Inc. | 645.22 Million USD | 92.623% |
| Silver Spike Investment Corp. | 3 Million USD | -1481.54% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 95.33% |
| Journey Medical Corporation | 56.49 Million USD | 15.748% |
| Alimera Sciences, Inc. | 107.35 Million USD | 55.659% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -123.317% |
| Assertio Holdings, Inc. | 148.41 Million USD | 67.927% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -2410.684% |
| Embecta Corp. | 2.03 Billion USD | 97.662% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -460.644% |
| Procaps Group, S.A. | 462.06 Million USD | 89.698% |
| PainReform Ltd. | 2.69 Million USD | -1668.922% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 72.546% |
| Hempacco Co., Inc. | 18.82 Million USD | -152.899% |
| Talphera, Inc. | 6.29 Million USD | -656.784% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 93.241% |
| Alvotech | 1.88 Billion USD | 97.471% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 94.301% |
| Kamada Ltd. | 109.96 Million USD | 56.713% |
| Indivior PLC | 1.95 Billion USD | 97.56% |
| Currenc Group, Inc. | 177.67 Million USD | 73.209% |
| Evoke Pharma, Inc. | 9.64 Million USD | -393.38% |
| Flora Growth Corp. | 17.22 Million USD | -176.4% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -460.644% |
| Evolus, Inc. | 209.68 Million USD | 77.299% |
| HUTCHMED (China) Limited | 536.38 Million USD | 91.125% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 94.55% |
| Akanda Corp. | 12.66 Million USD | -275.737% |